A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia

Grant

Date/time Interval

  • March 1, 2016 - June 15, 2018
  • Total Award Amount

  • 22500.00
  • Direct Costs

  • 17857.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator